The Oxford Biomedica share price is up 80% in a year. Here’s what I’d do

The Oxford Biomedica (LON: OXB) share price has soared more than 600% in five years. Could there be be a lot more to come?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At the time of writing, the Oxford Biomedica (LSE: OXB) share price has stormed ahead 82% over the past 12 months, and 170% over two years. And over the past five years, we’ve seen a massive 630% gain.

The latest bullish sentiment appears to stem from record first-half results released in September, which showed a surge in earnings. A 139% rise in revenue, to £81.3m, led to an operating profit of £19.7m, from £5.8m a year previously.

On an EBITDA basis, it’s even more impressive. The half brought in a figure of £27.1m, from an EBITDA loss of £0.4m in H1 2020. My Motley Fool colleague Zaven Boyrazian has dug more deeply into the results, so I won’t repeat them here. I just want to look at the bigger investment picture.

Oxford Biomedica specialises in gene-based biotechnology. And its key technological development is its LentiVector drug development platform. That’s used by pharmaceuticals companies for R&D, including big names like Novartis and AstraZeneca.

Oxford Biomedica strikes me as something of a picks and shovels investment. You know, when there’s a gold rush, those selling the digging tools make their money whoever finds the shiny stuff. It’s perhaps not quite like that here, but I do see something similar.

Biotechnology platform

The LentiVector financial model renders things a little differently from straight picks and shovels sales. Customers pay an initial licence fee. And then further cash comes from royalties should the drugs being developed turn into commercial successes. That makes for a nice potential long-term income stream. But much of it will come from the successful users of the technology.

So where are the current big profits coming from? Oxford Biomedica has also been doing some manufacturing, of AstraZenenca’s Covid-19 vaccine, and that contributed strongly to those first-half profits.

It does create some concern for me over the Oxford Biomedica share price strength. Those H1 results show revenue from licences, milestones and royalties of just £5.7m, down from £10.6m. That’s only a small fraction of total revenue. The Covid vaccine deal will probably keep the cash coming for some time yet. But it’s going to wind down eventually, surely.

Oxford Biomedica share price valuation

If the current valuation is driven by those vaccine profits, I can see a risk of price falls when that happens. So what does the valuation look like? Well, simply doubling up first-half EPS, and going on the current Oxford Biomedica share price, I get a forward P/E of around 35.

The company says it expects EBITDA in the second half to be below the H1 figure, due to “an increase in research and development, administrative and bioprocessing costs“. So the real forward P/E should be higher than my guess. I even see some forecasts suggesting around twice that valuation, with a P/E of close to 70.

A company in transition

Right now, Oxford Biomedica is in something of a transitional phase. It currently has its manufacturing capacity to bring in the shorter-term cash. And I can see further opportunities there. But long term, it’s surely all about the LentiVector technology and its licensing progress and royalty income.

On balance, I see attractive potential here, but with a fair helping of risk. I’ll keep watching, in the hope of better buying opportunities in the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

£3k in savings? Investors could consider putting it here for juicy second income

Jon Smith talks through how investors could buy dividend stocks with yield potential in excess of 6.5% for second income

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

Why the boohoo share price soared by almost 14% in November

Is troubled online fashion retailer boohoo beginning a turnaround that may cause the share price to rocket through 2025 and…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

Here’s how saving £5.40 a day could net me £1,971 yearly passive income for life

The price of a cup of coffee seems to have broken the £5 mark. Is it time to put that…

Read more »

Investing Articles

2 top FTSE 100 stocks surging to record highs (hint — not Rolls-Royce)!

Ben McPoland takes a closer look at a pair of high-performing FTSE 100 stocks that continue to enrich long-term shareholders.

Read more »

Investing Articles

A cheap FTSE 100 share to consider buying for the next 10 years!

This FTSE 100 share has pride of place in my portfolio. Here's why I think it could be a top…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Down 44% in 2 months! Is this FTSE 250 green energy pioneer priced too cheaply?

After a sharp tumble in recent months, this FTSE 250 company with a growing order book is almost 90% below…

Read more »

Investing Articles

Investing a £20k Stocks and Shares ISA in this high-yielder might give me a £2,000 annual income

Harvey Jones is now wondering whether to pour his entire Stocks and Shares ISA allowance into a single FTSE 100…

Read more »

Investing Articles

Saving £20k in an ISA? Here’s how I’m aiming to turn that into a stunning £2,035 monthly passive income

Harvey Jones is keen to build a high and rising passive income by investing in a balanced spread of top…

Read more »